Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO 2020 Notebook: Conversations On Rebates, Racism And Remote Working

Executive Summary

News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.

You may also be interested in...



COVID-19 Pandemic Turns Big Pharma Rivals Into Bedfellows

Industry leaders at a PhRMA briefing talked about the unprecedented level of partnership going into developing COVID-19 vaccines and treatments – not to mention making enough of them.

Biopharmas Manage To Deal During Pandemic

M&A activity faces numerous hurdles during the COVID-19 pandemic but companies are finding different ways to negotiate, conduct due diligence and get deals completed, BIO 2020 speakers said.

AstraZeneca Gilead Merger Intriguing But Unlikely

The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel